XBiotech's Phase 2 Study of Bermekimab to Treat Atopic Dermatitis Meets Primary, Secondary Endpoints

Press/Media

Period12 Dec 2018

Media coverage

1

Media coverage

  • TitleXBiotech's Phase 2 Study of Bermekimab to Treat Atopic Dermatitis Meets Primary, Secondary Endpoints
    Media name/outletMidnight Trader Live Briefs
    Country/TerritoryUnited States
    Date12/12/18
    PersonsAlice Gottlieb
View all 1
View less